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ABSTRACT 
Objective: A rapid and selective quantitative method was developed and validated in human plasma for urapidil pharmacokinetic study in healthy 
Indian volunteers. 
Methods: The ultra-performance liquid chromatography–tandem mass spectrometry (UPLC-MS/MS) method with solid-phase extraction technique 
utilized Strata X 33µ polymeric reversed phase (30 mg/mL), extraction cartridge. Simple gradient chromatographic conditions and selective 
reaction monitoring in mass spectrometric detection enabled accurate and precise measurement of urapidil at nanogram levels in 0.1 mL of human 
plasma. The method used a deuterium labeled internal standard. 
Results: The method was validated for a linear range of 5–500 ng/mL for urapidil with a correlation coefficient ≥ 0.99 The intra-run and inter-run 
precision and accuracy were within 10%. The overall recoveries for urapidil and urapidil D4 were more than 90%. The urapidil was found to be 
stable in plasma matrix and aqueous media.  
Conclusion: The developed and validated method was specific, sensitive and reproducible in the analysis of clinical samples interspersed with 
quality control samples under freshly prepared calibration standards. The method was applied for the determination of the pharmacokinetic 
parameters of urapidil following a single oral administration of urapidil 60 mg capsules in nineteen healthy Indian male volunteers for fasting and 
fed study. 




propylamino}-1, 3-dimethyluracil), is a derivative of 
pyrimidinedione. It has a melting point range of 156-158 °C and the 
pKa is 7.01. Its molecular formula and molecular mass is 
C20H29N5O3 and 387.48 g/mol, respectively [1]. Urapidil is a 
sympatholytic antihypertensive drug. It blocks peripheral α1-
adrenergic receptors and also stimulates central serotonin 1A (5-
hydroxytryptamine) (5-HT1A) receptors [2]. It prevents 
vasoconstrictive action of catecholamines resulting peripheral 
vasodilation to decrease blood pressure. The absolute bioavailability 
is approximately 72% and the protein binding is 80%. Urapidil 
divides rapidly over the tissues. Urapidil is metabolised mainly to 
the p-hydroxy-urapidil, whose pharmacology activity in humans is 
not known. In addition, slightly (4%) the O-desmethyl urapidil 
formed has the same activity as urapidil. 50-70% of the amount of 
renal urapidil is excreted, about 15% as unchanged drug [3-7].  
Reported literature has mentioned, to assess the effect of urapidil on 
fibrinogen concentration [8]. The pharmacological animal studies 
[9-13] and in patient studies [14-16] for the pharmacokinetics and 
pharmacodynamic evaluation of urapidil was done in last decades. 
Veltkamp AC et al. reported the post-column ion-pair extraction to 
the on-line radiometric determination of [(14)C]-urapidil and its 
main metabolises in reversed-phase liquid chromatography (LC) 
[17]. Large sample volume (1-2 mL) and injection volume (100-50 
µL) was used into the automated pre-column system, followed by 
high-performance liquid chromatography with electrochemical 
detection by Zech K et al. [18]. A sensitive flow-injection (FI) 
chemiluminescence (CL) method was developed for the 
determination of urapidil in pharmaceutical preparation, human 
urine, and serum by Q. Yue et al. [19]. The urapidil was analyzed in 
rat plasma by LC-MS/MS and liquid-liquid extraction protocol is 
followed for a linearity range of 0.1-500 ng/mL by Nirogi R et al. 
[20]. The aliquots of 0.3 mL plasma was used for Liquid-liquid 
extraction by ethyl acetate and injected 20 µL to detect urapidil in 
human plasma in which the linearity range was 2–2503.95 ng/mL 
and recovery was 74.53%. This method was developed and validated 
by Ambavaram VBR et al. [21]. As the described methods were liquid-
liquid extraction, it was felt necessary to develop a simple, specific, rapid, 
selective and sensitive analytical method for the quantification of 
urapidil in human plasma using solid phase extraction with as little as 
0.1 mL sample volume. 
This paper describes development and validation of a LC–MS/MS 
method for the quantification of urapidil in human plasma having 
reduced plasma volume and analytical run time with a lower limits 
of quantification (LOQ) 5.201 ng/mL. Urapidil D4 was used as 
internal standard.  
MATERIAL AND METHODS 
Chemicals and reagents 
The analytical standards of urapidil and urapidil D4 were 
obtained from Clearsynth (Mumbai, India). High purity water 
was prepared in-house using a Milli-Q water purification system 
obtained from Millipore (Bangalore, India). Gradient grade 
methanol and acetonitrile were purchased from Merck 
(Darmstadt, Germany). GR-grade orthophosphoric acid and 
reagent grade ammonium formate were purchased from Merck 
(Darmstadt, Germany). Drug-free (blank) buffered human 
plasma was obtained from Drug Monitoring Research Institute 
(Mumbai, India) and was stored at –20°C prior to use. 
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Calibration curves  
Stock solutions of urapidil and internal standard, urapidil D4 were 
prepared in methanol:water (50/50, v/v) at the concentration of 
250 µg/mL and 150 µg/mL, respectively. Secondary and working 
standard solutions were prepared from stock solutions by dilution 
with methanol:water (50/50, v/v) using serial dilution method. 
These diluted working standard solutions were used to prepare the 
calibration curve and quality control (QC) samples in human plasma. 
A nine-point standard calibration curve for urapidil was prepared by 
spiking 2% of urapidil working standard solution in the blank 
screened plasma. The calibration curve ranged from 5.201 to 
1501.188 ng/mL. Quality control samples were prepared at four 
concentration levels-5.201 ng/mL for Lower Limit of Quantification 
Quality Control (LLOQQC), 14.962 ng/mL for Low Quality Control 
(LQC), 610.679 ng/mL for Medium Quality Control (MQC) and 
1197.409 ng/mL for High Quality Control (HQC) samples for urapidil 
from the stock solutions. 
Sample preparation 
A 0.1 mL aliquot of urapidil spiked on human plasma sample was 
mixed with 50 µL of internal standard working solution equivalent 
to 250 ng/mL of urapidil D4 as an internal standard. Then, added 0.9 
mL of 2% ortho phosphoric acid and vortexed to mix. The sample 
mixture was loaded into a Strata X 33µ polymeric reversed phase 
(30 mg/mL), extraction cartridge that was pre-conditioned with 1.0 
mL methanol followed by 1.0 mL water. The extraction cartridge 
was washed with 1.0 mL water followed by 1.0 mL of 5% methanol 
in water. Both urapidil and urapidil D4 were eluted with 1 mL of 
methanol; 2 µL of the sample was injected into the LC–MS/MS 
system.  
Liquid chromatography and MS parameters 
Chromatographic separation was carried out on Waters UPLC with 
Betasil-C18 (50mm x 4.6mm, 5µm) purchased from Thermo 
scientific, United States. A degassed mobile phase consisting of 
acetonitrile: methanol (70:30, v/v) (A) and 10mM ammonium 
formate pH about 4.50±0.05 (B) was delivered with a flow rate of 0.5 
mL/min using solvent composition gradient. Each analytical run was 
started at 40% A up to 0.2 min followed by a liner gradient to 60% A 
over 0.6 min, held at 60% A for 1.2 min, shifted to linear to 40% A 
over 0.2 min and then held constant until the end of the run for 
column equilibration to take on the next analytical run. The total run 
time for each sample analysis was 2.5 min. The gradient elution 
program of chromatographic separation is presented in Table 1a. 
The column oven temperature was kept 40 ºC. Mass spectra were 
obtained using a Xevo TQ-S mass spectrometer, a triple-stage 
quadrapole-mass-analyzer with photomultiplier detector equipped with 
electro spray ionization (ESI) source (Waters Ltd. UK) running on 
positive ion mode. The mass spectrometer was operated in the multiple 
reaction-monitoring (MRM) scan mode. The data acquisition was 
ascertained by MassLynx 4.1 software. The details for ion source and 
analyte dependent MS parameters are presented in Table 1b. 
 
Table 1a: Gradient elution program of chromatographic 
separation. 






0 0.0 0.5 40 60 
1 0.2 0.5 40 60 
2 0.8 0.5 60 40 
3 2.0 0.5 60 40 
4 2.2 0.5 40 60 
5 2.5 0.5 40 60 
 
Method validation 
The method was validated for specificity, selectivity, sensitivity, 
linearity, precision, accuracy, recovery, stability and matrix effect 
meeting the global regulatory requirements [22-23]. Specificity was 
performed by analyzing the human male blank plasma samples from 
different sources (or donors) to test for interference at the retention 
time of urapidil and internal standard, urapidil D4. Selectivity was 
performed by spiking concomitant drugs like ranitidine, 
paracetamol, ibuprofen and aspirin. The plasma samples were then 
processed and analyzed to investigate possible interference. 
Sensitivity was determined by analyzing six replicates of blank 
human plasma spiked with the analyte at the lowest level of the 
calibration curve. The intra-run and inter-run accuracy were 
determined by replicate (n=6) analysis of three quality control 
samples and at LOQ that were extracted from the sample batch. The 
intra-run (within batch) precision and accuracy were evaluated by 
analysis of six replicates at four concentrations in a same analytical 
run. The inter-run precision and accuracy of the calibration 
standards were assessed using seven calibration curves. The inter-
run (between-batch) precision and accuracy were evaluated after 
repeated analysis in different analytical runs in different days and on 
different instrument. 
 
Table 1b: Ion source and analyte-dependent MS parameters 
Ion source  
Capillary voltage   3.20 kV   
Source temperature 150 ºC  
Desolvation temperature 500 ºC  
Desolvation gas flow  1000 L/hr  
Cone gas flow  150 L/hr  
Polarity mode   Positive   
Analyte dependent     
   Urapidil   Urapidil-D4 
Precursor ion (m/z)  388.2 392.2 
Product ion (m/z)  190.1 190.1 
Cone voltage (V) 18 20 
Q1 Pwª (amu)  2.8 14.8 
Q3 Pwb (amu)  2.8 14.7 
Collision energy   36 32 
ª Quadrapole 1 high and low mass resolution parameters. 
b Quadrapole 3 high and low mass resolution parameters. 
 
Accuracy was defined as the percent of relative error ( RE% ) and 
was calculated using the formula )/100()(% TTERE ×−= , where 
E  is the experimentally determined concentration and T  is the 
theoretical concentration. Assay precision was calculated by using 
the formula 100)/(% ×= MSDRSD , where RSD% is percent of 
relative standard deviation, M  is the mean of experimentally 
determined concentrations and SD  is the standard deviation of M . 
The extraction efficiencies of urapidil and urapidil D4 were 
determined by comparing the peak area of extracted analytes to the 
peak area of non-extracted standards (analyte spiked post 
extraction in blank plasma).  
The processed sample stability was evaluated by comparing the 
extracted fresh plasma samples which were injected immediately 
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(time 0), with the samples that were re-injected after keeping in the 
auto sampler at 10°C for specific duration of time. The stability of 
spiked human plasma stored at room temperature (bench-top 
stability) was evaluated by comparing the mean of back calculated 
concentrations of the samples kept on bench with freshly prepared 
extracted samples. The freeze-thaw stability was conducted by 
comparing the stability samples that had been frozen and thawed 
two times stored at –30°C, with freshly spiked quality control 
samples. The long-term stability of spiked human plasma was 
evaluated by analyzing low, medium and high quality control 
samples that were stored at –30°C for long duration together with 
freshly spiked calibration standard and quality control samples. 
Stability was determined by calculating the %change and was 
calculated using the formula CCSChange /100)(% ×−= , where S  
is the mean stability sample concentration and C  is the mean freshly 
prepared or comparison sample concentration. Analytes were 
considered stable if the %Change were within ±15% of the freshly 
prepared or comparison sample. 
Matrix effect was evaluated with eight different lots of plasma 
containing K2EDTA as anticoagulant including one hemolysed lot 
and one lipemic plasma lot. Three post spiked samples each of LQC, 
MQC and HQC were prepared from different lots of plasma (in total 
24 samples). Aqueous (unextracted) spiked samples for urapidil and 
urapidil D4 at LQC, MQC and HQC levels were prepared in elution 
solution considering zero matrix effect. The post-spiked extracted 
LQC, MQC and HQC samples along with six replicate injections of 
aqueous un-extracted LQC, MQC and HQC levels were analyzed. The 
matrix effect was evaluated by calculating the matrix factor for area 
response of urapidil and urapidil D4 and IS normalized matrix factor 
for mean area ratio of urapidil and urapidil D4.  
This was performed with the aim to see the matrix effect of these 
different lots of plasma on the %RSD of mean matrix factor for 
analyte area, IS area and IS normalized area ratio. It was considered 
there was no matrix effect if the %RSD for mean matrix factor was 
less than 15% at each level for analyte area, IS area and IS 
normalized area ratio.  
The weighting factor for plotting the linear regression curve for the 
calibration standards was selected based on the ‘Least sum of 
squared residuals’. For this a calibration curve was plotted using the 
weighting factor-1/X and 1/X2 to obtain the calculated 
concentrations for each standard. The residual ( RE% ) for each 
calibration standard was obtained. Each residual was squared and 
the sum of squared residuals was calculated for each empirical 
weights. The weighting factor which results in the least sum was 
used for plotting the linear curves [24]. 
RESULTS AND DISCUSSION 
Tuning and Chromatography Optimization 
The development was initiated from mass optimization with ESI 
(electrospray ionization) in both positive and negative modes. The 
signal in positive ionization mode has shown a significant response 
but the baseline noise was very high. To reduce the baseline signal 
the heated nebulization with APCI (atmospheric pressure chemical 
ionization) source was also tried but the signal was decreased to ten 
times as compared to ESI. The inconsistency was also observed in 
APCI mode. So as a conclusion considering the signal ESI positive 
mode was considered and proceed for further optimization using 
three different mass transitions (m/z) as 388.2/190.1, 388.2/205.3, 
388.2/233.3 for urapidil and 392.2/190.1, 392.2/200.1, 392.2/237.2 
for urapidil D4. The final MRM parameters of the urapidil and its 
internal standard were set at m/z 388.2/190.1 and 392.2/190.1, 
respectively. The selected fragment ions of each compound, as 
product ion to be monitored are indicated in Fig. 1.  
Sample extraction trials were initiated with precipitation, liquid-
liquid extraction (LLE) and solid phase extraction (SPE) and also 
with hybrid-SPE technique using zirconium cartridges, in all trials 
the interference in blanks could not be eliminated. The buffers from 
acid pH to basic pH were used in LC but none of the conditions could 
mitigate the interference in blank plasma which may be due to the 
co-elution of the phospholipids. Trials for sample extraction using 
different LLE solvents were tried and also plasma sample treated 
from acidic to basic pH.  
Further to the mass optimization and extraction trials, the 
chromatography LC conditions were optimized. The use of buffers 
like ammonium acetate, ammonium formate has shown broad peak 
shape with C18 column. The use of acetonitrile and methanol 
combination along with 10mM ammonium formate pH about 
4.50±0.05 has shown the best signal-to-noise (S/N) among all the 
mobile phases. Use of Betasil-C18 (50mm x 4.6mm, 5µm) column 
enabled use of high flow rate, which resulted in low run time as low 
as 2.5 min with better peak symmetry and signal of analytes. The 
compound post to injection has shown carryover and needed a 
strong cleaning, hence the needle and seal wash optimization was 
also critical. The equal proportions of acetonitrile, methanol and 
water with 0.01% of isopropyl alcohol (IPA) used as strong and 
weak needle wash to remove carryover from autosampler. 
Autosampler carryover was evaluated for aqueous and extracted 
samples by injecting blank samples after highest concentration 
(ULOQ) standard. No carryover was observed at retention time of 
urapidil and urapidil D4 in blank samples injected after highest 
concentration. Also, the purity of deuterium labeled compound was 
confirmed by injecting urapidil D4 alone in optimized LC and MS 
conditions and no significant interference was observed at retention 





Fig. 1: ESI product ion mass spectra of the precursor ions of (A) 
urapidil and (B) urapidil D4. 
 
Specificity 
Utilization of predominant product ions for each compound 
enhanced mass spectrometric specificity. The mass transition ion-
pair was selected as, 388.2 → 190.1 for urapidil and 392.2 → 190.1 
for urapidil D4. The product ions selected were specific for urapidil 
and urapidil D4, respectively.  
Chromatographic specificity of the method was demonstrated by the 
absence of endogenous interfering peaks at the retention times of 
urapidil and its internal standard in eight different lots of extracted 
blank plasma including one haemolysed and one lipemic plasma. 
Representative chromatograms of extracted blank plasma, extracted 
plasma samples containing 5.201 ng/mL urapidil (low standard) and 
plasma sample from subjects are presented in Fig. 2.  
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Fig. 2: Representative chromatograms of (A) extracted blank 
plasma sample, (B) extracted plasma LLOQ sample and (C) 
extracted subject sample for time point collected at 4.50 h. 
Linearity  
The peak area ratios (area of urapidil/area of urapidil D4) of 
calibration standards were proportional to the concentration of 
analytes in each assay over the nominal concentration range of 
5.201–1501.188 ng/mL for urapidil. The calibration curves were 
found to be linear and were well described by least squares lines. A 
weighting factor of 1/concentration2 was chosen to achieve 
homogeneity of variance.  
The correlation coefficients were ≥09980 (n=7) for urapidil. The mean 
(±SD) slopes and intercept of the calibration curves (n=7) for urapidil 
were 0.00884526 (±0.00015313) and 0.00415583 (±0.00186341), 
respectively. The mean accuracy and precision for back calculated 
concentrations of each standard calculated from calibration curve 
tabulated in Table 2a. 
Sensitivity (lower limit of quantification) 
The LOQ is defined as the lowest concentration of the calibration 
standard yielding accuracy ±20% and precision of ≤ 20%. The LOQ 
for urapidil was 5.201 ng/mL. These data are tabulated in Table 2b 
for urapidil. The intra-run precision at the LOQ plasma samples 
containing urapidil was 0.91%. The intra-run accuracy (%RE) at the 
LOQ plasma samples containing urapidil was –0.88%. 
Precision and accuracy 
The intra-run precision was ≤1.34% and intra-run accuracy was ≤2.23 
for urapidil (Table 2b). The inter-run precision and accuracy were 
determined by pooling all individual assay results of replicate (n= 6) QC 
samples over the four separate batch runs. The inter-run precision was 
≤3.00. The inter-run accuracy was ≤3.18 for urapidil (Table 2b). 
Recovery 
Six replicates at low, medium and high quality control 
concentrations for urapidil were prepared for recovery 
determination. The mean recovery for urapidil was 95.43% with 
precision of 7.98%. The mean recovery for urapidil D4 was 96.04%. 
Stability 
The bench top stability, process stability, freeze-thaw stability and long 
term stability in matrix of urapidil in plasma were investigated by 
analyzing quality control samples in replicates (n=6) at LQC, MQC and 
HQC levels. Process stability results indicated that processed samples 
were stable at least for 8 h at 10°C in autosampler of UPLC system. 
Results of bench-top stability for urapidil were found stable for at least 3 
h at room temperature in plasma samples. Freeze and thaw stability 
results indicated that the repeated freezing–thawing (two cycles) did not 
affect the stability of urapidil for samples stored at –30°C temperatures. 
Long-term stability of urapidil in plasma was performed at LQC, MQC 
and HQC levels and was found to be stable for at least 6 days at –30°C. 
Matrix effect 
The matrix factor for urapidil and urapidil D4 was calculated by 
comparing the area response for analyte, IS and IS normalized area 
ratio observed in post spiked samples with that of unextracted 
samples at LQC, MQC and HQC levels and the matrix effect was 
evaluated from the %RSD of mean matrix factor at each level. Three 
quality control samples at each level were analyzed and the %RSD of 
the samples analyzed was found ≤7.33% for analyte area, IS area 
and IS normalized area ratio for urapidil and urapidil D4 (Table 3).
 
Table 2a: Calibration curve back calculated concentrations of urapidil (n= 7). 
Standard conc. (ng/mL) Mean calculated conc. ±SD (ng/mL) RSD(%) RE(%) 
5.201 5.203 ±0.156 3.00  0.04 
10.402 10.437 ±0.644 6.17 0.34 
77.049 74.821 ±1.874 2.50 –2.89 
154.097 152.194 ±2.938 1.93 –1.23 
308.195 313.636 ±1.715 0.55 1.77 
616.389 617.014 ±5.935 0.96 0.10 
906.455 920.950 ±17.328 1.88 1.60 
1208.606 1209.315 ±26.197 2.17 0.06 
1501.188 1504.752 ±37.089 2.46 0.24 
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Table 2b: Intra-run (within-batch) and Inter-run (between batch) precision and accuracy of urapidil in human plasma (n=6). 
Spiked conc. 
(ng/mL) 
Intra-run precision and accuracy Inter-run precision and accuracy 
Mean calculated conc. ±SD 
(ng/mL) 
RSD (%) RE (%) Mean calculated conc. ±SD 
(ng/mL) 
RSD(%) RE(%) 
5.201 5.155 ±0.047 0.91 –0.88 5.203 ±0.156 3.00  0.04 
14.962 14.750 ±0.198 1.34 –1.42 14.486 ±0.403 2.78 –3.18 
610.679 609.290 ±5.234 0.86 –0.23 607.098 ±9.316 1.53 –0.59 
1197.409 1171.938 ±13.656 1.17 –2.13 1168.837 ±17.001 1.45 –2.39 
 
Table 3: Matrix effect for urapidil and urapidil D4 (n=8). 
Parameter LQC  MQC  HQC   
  Mean matrix factor 
±SD 
RSD (%) Mean matrix factor 
±SD 
RSD (%) Mean matrix factor 
±SD 
RSD (%) 
Analyte area 0.989 ±0.033 3.34 1.064 ±0.077 7.24 1.038 ±0.037 3.56 
IS area 1.022 ±0.032 3.13 1.078 ±0.079 7.33 1.058 ±0.045 4.25 
IS normalized 0.967 ±0.010 1.03 0.987 ±0.005 0.51 0.981 ±0.009 0.92 
 
Hence, this clearly proved that the elution of endogenous matrix 
peaks during the run had no effect on the quantification of urapidil. 
Therefore, the method of extraction of urapidil from plasma was 
robust enough and gave accurate and consistent results when 
applied to subject samples. 
Application of method 
The proposed developed method was applied to the determination 
of urapidil in human plasma samples in Indian male volunteers. 
Plasma samples were periodically collected after a single oral dose 
administration of urapidil 60 mg capsule to healthy male volunteers 
in each phase under fasting (9 subjects) and fed (10 subjects). The 
time periods at which the plasma samples were drawn were 0.00, 
1.00, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 5.50, 6.00, 8.00, 10.00, 
12.00, 16.00 and 24.00 h after under fasting.  
The time periods at which the plasma samples were drawn were 
0.00, 1.00, 2.00, 3.00, 4.00, 4.50, 5.00, 5.50, 6.00, 6.50, 7.00, 8.00, 
10.00, 12.00, 16.00 24.00 and 36.00 h under fed. A total of 628 
human plasma samples from nineteen male volunteers were 
analyzed along with calibration standards and QC samples. Seven 
calibration curves were made for sample quantification with twenty 
six sets of interspersed LQC, MQC and HQC samples. No significant 
interference peak was found in predose samples for all volunteers. 
The mean (±SD) plasma maximum concentrations (Cmax) obtained 
for the urapidil test and reference formulations were 976.028 
(±222.301) ng/mL and 634.531 (±125.706) ng/mL, respectively 
under fasting. The mean (±SD) plasma maximum concentrations 
(Cmax) obtained for the urapidil test and reference formulations were 
1005.609 (±287.510) ng/mL and 887.864 (±239.801) ng/mL, 
respectively under fed.  
 
Table 4a: Pharmacokinetic parameters for fasting study (n=9). 




t1/2 (h) kel (h-1) 
 
Test (T) Mean 976.0297 3.944 5907.1604 6084.7484 4.1779 0.1667 
 SD 222.3081 0.58 1340.6645 1417.8319 0.3109 0.0123 
 RSD(%) 22.78 14.79 22.70 23.30 7.44 7.38 
Reference (R) Mean 634.5314 3.944 5312.6941 5720.4004 5.6645 0.1240 
 SD 125.7061 0.53 857.5358 919.6214 0.6898 0.0150 
  RSD(%) 19.81 13.36 16.14 16.08 12.18 12.11 
 
The mean plasma concentration–time profile following a 60 mg oral 
dose of urapidil to human subjects is shown in Fig. 3 and the 





Fig. 3: Mean plasma concentration –time profile following a 60 
mg oral dose of urapidil capsules in human subjects under (A) 
fasting and (B) Fed. 
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Table 4b: Pharmacokinetic parameters for fed study (n=10). 
Drug Statistics Cmax (ng/mL) tmax (h) AUC0-t (ng*h/mL) AUC0-∞ 
(ng*h/mL) 
t1/2 (h) kel (h-1) 
 
Test (T) Mean 1005.6091 5.100 6266.8428 6374.4837 4.6332 0.1641 
 SD 287.5095 0.57 2343.0736 2399.6547 1.5153 0.0502 
 RSD(%) 28.59 11.13 37.39 37.64 32.70 30.60 
Reference (R) Mean 887.8638 5.350 6229.6265 6355.9640 5.2762 0.1371 
 SD 239.8011 0.47 2191.0869 2244.2059 1.0577 0.0324 
  RSD(%) 27.01 8.87 35.17 35.31 20.05 23.65 
Cmax , the maximum plasma concentration, tmax , the time to reach Cmax, AUC0-t , the area under the plasma concentration –time curve from time zero to 
the last sampling point, AUC0-∞ , , the area under the plasma concentration –time curve from time zero to infinity, t1/2 , elimination half life, kel , 
elimination rate constant. 
 
CONCLUSION 
A first of its kind of solid phase extraction analytical method using 
LC–MS/MS system was developed for the determination of urapidil 
in human plasma. The described method was simple, specific, rapid, 
reproducible and sensitive method with a LOQ of 5 ng/mL for 
urapidil. 
It was concluded that this sensitive and specific method was 
applicable for the quantitative determination of urapidil in human 
plasma in pharmacokinetic and bioavailability studies of urapidil. 
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